Vevorisertib

Vevorisertib (ARQ 751) is an orally active, potent and selective pan-AKT serine/threonine kinase inhibitor against AKT1 (IC50=0.55 nM), AKT2 (IC50=0.81 nM), and AKT3 (IC50=1.31 nM) . Vevorisertib, as a single agent or in combination with other anti-cancer agents, can be used for the research of solid tumors with PIK3CA / AKT / PTEN mutations[1][2][3][4].

Product Specifications

CAS Number

[1416775-46-6]

Product Name Alternative

ARQ 751

UNSPSC

12352005

Target

Akt; Ser/Thr Protease

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vevorisertib.html

Purity

98.03

Solubility

DMSO : 6.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC1=C(C=CC=N1)C2=NC3=CC=C(C4=CC(N(CC5)CCC5N(C)C(C)=O)=CC=C4)N=C3N2C6=CC=C(C7(CCC7)N)C=C6

Molecular Formula

C35H38N8O

Molecular Weight

586.73

References & Citations

[1]Vevorisertib (ARQ 751) (4440-001) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations.|[2]ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.|[3]Abstract A034: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751|[4]Abstract 374: In vitro and in vivo anti-tumor activity of ARQ 751, a potent and selective AKT inhibitor